Ruxolotinib

DRUG2 trials

Sponsors

French Innovative Leukemia Organisation

Conditions

Myelofibrosis

Phase 1

Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg

CompletedNCT02742324

French Innovative Leukemia OrganisationMyelofibrosis

Start: 2016-03-31End: 2021-12-31Updated: 2022-07-27

Phase 2

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

CompletedNCT01795677

French Innovative Leukemia OrganisationMyelofibrosis

Start: 2012-12-31End: 2019-03-31Updated: 2022-07-27

Related Papers

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Blood2022-11-1519 citations

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

Haematologica2019-12-26103 citations

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Blood2018-11-2926 citations

Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc

Blood2013-11-1563 citations